BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21358344)

  • 1. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
    Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
    J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
    J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducibility of histological subtyping of malignant pleural mesothelioma.
    Brčić L; Jakopović M; Brčić I; Klarić V; Milošević M; Sepac A; Samaržija M; Seiwerth S
    Virchows Arch; 2014 Dec; 465(6):679-85. PubMed ID: 25300229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
    Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
    Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
    Gill RR; Umeoka S; Mamata H; Tilleman TR; Stanwell P; Woodhams R; Padera RF; Sugarbaker DJ; Hatabu H
    AJR Am J Roentgenol; 2010 Aug; 195(2):W125-30. PubMed ID: 20651171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.
    Kadota K; Suzuki K; Colovos C; Sima CS; Rusch VW; Travis WD; Adusumilli PS
    Mod Pathol; 2012 Feb; 25(2):260-71. PubMed ID: 21983936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade.
    Zhang YZ; Brambilla C; Molyneaux PL; Rice A; Robertus JL; Jordan S; Lim E; Lang-Lazdunski L; Begum S; Dusmet M; Anikin V; Beddow E; Finch J; Asadi N; Popat S; Quesne JL; Husain AN; Cookson WOCM; Moffatt MF; Nicholson AG
    Histopathology; 2020 Sep; 77(3):423-436. PubMed ID: 32333813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
    Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
    J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility for histologic parameters in peritoneal mesothelioma.
    Hartman DJ; Borczuk A; Dacic S; Krasinskas A
    Hum Pathol; 2017 Sep; 67():54-59. PubMed ID: 28712777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
    Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
    Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
    Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
    Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
    Johansson L; Lindén CJ
    Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.